Asthma: Updated NICE Guidelines: Diagnosis, Monitoring, and Chronic Management of Asthma

Introduction

On November 27, 2024, the National Institute for Health and Care Excellence (NICE), in collaboration with the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN), released updated guidelines for the diagnosis, monitoring, and management of chronic asthma in adults, young people, and children. These guidelines aim to standardize care, reduce misdiagnosis, and improve patient outcomes by integrating the latest evidence-based practices.

This update addresses key aspects of asthma care, including diagnosis, pharmacological treatment, environmental impact, and self-management strategies, providing clinicians with a structured approach to enhance patient care. The guidance emphasizes precision in diagnosis, sustainability in treatment choices, and empowerment of patients to self-manage their condition effectively.

Key Highlights of the 2024 NICE Asthma Update for Clinicians

1. Diagnosis

   • Objective Testing: Clinicians are urged to use a thorough clinical history alongside standardized objective tests like spirometry and fractional exhaled nitric oxide (FeNO) measurements to improve diagnostic accuracy.
   • Goal: Reduce overdiagnosis and misdiagnosis, which can lead to inappropriate treatment and unnecessary healthcare costs.
   • 
     

2. Pharmacological Management

   • Updated Treatment Paradigm: Move away from the routine use of short-acting beta-agonists (SABAs), commonly known as “blue inhalers.”
   • Rationale: SABAs address symptoms but fail to manage underlying inflammation and...